{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:17:28Z","timestamp":1790057848604,"version":"4.0.1"},"reference-count":16,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Dupilumab is a biologic approved by the United States Food and Drug Administration (US FDA) for the treatment of atopic dermatitis. While it is an effective medication for eczema, ocular side effects are common in patients receiving dupilumab therapy. Greater consideration is needed when evaluating these individuals for corneal refractive surgery. Dupilumab patients may suffer from atopy, a condition that also merits consideration in those desiring refractive surgery. Additional testing and careful consideration are needed, as these patients have an increased risk of dry eye syndrome, keratoconus, cataracts, diffuse lamellar keratitis, viral keratitis, and perioperative infection. This commentary discusses the current understanding of dupilumab ocular side effects and investigates factors to consider when evaluating these patients for corneal refractive surgery.<\/jats:p>","DOI":"10.3390\/jcm11123273","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T02:25:33Z","timestamp":1654827933000},"page":"3273","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Corneal Refractive Surgery Considerations in Patients on Dupilumab"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-6250","authenticated-orcid":false,"given":"Majid","family":"Moshirfar","sequence":"first","affiliation":[{"name":"Hoopes Vision Research Center, Hoopes Vision, 11820 S. State St., Ste. 200, Draper, UT 84020, USA"},{"name":"John A. Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT 84132, USA"},{"name":"Utah Lions Eye Bank, Murray, UT 84107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-9676","authenticated-orcid":false,"given":"Tanner","family":"Seitz","sequence":"additional","affiliation":[{"name":"Midwestern University, Glendale, AZ 85308, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Ply","sequence":"additional","affiliation":[{"name":"Hoopes Vision Research Center, Hoopes Vision, 11820 S. State St., Ste. 200, Draper, UT 84020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8852-4380","authenticated-orcid":false,"given":"Yasmyne C.","family":"Ronquillo","sequence":"additional","affiliation":[{"name":"Hoopes Vision Research Center, Hoopes Vision, 11820 S. State St., Ste. 200, Draper, UT 84020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip C.","family":"Hoopes","sequence":"additional","affiliation":[{"name":"Hoopes Vision Research Center, Hoopes Vision, 11820 S. State St., Ste. 200, Draper, UT 84020, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of Dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_2","first-page":"532","article-title":"Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis","volume":"43","author":"Pisano","year":"2018","journal-title":"Pharm. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaad.2020.11.042","article-title":"Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration","volume":"84","author":"Wang","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_4","unstructured":"FDA (2022, April 07). Dupixent Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761055lbl.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: Presentation, management and long-term sequelae","volume":"35","author":"Popiela","year":"2021","journal-title":"Eye"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2147\/OPTH.S336978","article-title":"Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients","volume":"16","author":"Tauqeer","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100550","DOI":"10.1016\/j.ajoc.2019.100550","article-title":"Dupilumab-associated blepharoconjunctivitis","volume":"16","author":"Paulose","year":"2019","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_8","first-page":"275","article-title":"Dupilumab Induced Limbal Stem Cell Deficiency","volume":"14","author":"Mehta","year":"2021","journal-title":"Int. Med. Case Rep. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1167\/iovs.14-15496","article-title":"IL-13 Stimulates Proliferation and Expression of Mucin and Immunomodulatory Genes in Cultured Conjunctival Goblet Cells","volume":"56","author":"Henriksson","year":"2015","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.preteyeres.2018.11.007","article-title":"Reconsidering the central role of mucins in dry eye and ocular surface diseases","volume":"71","author":"Baudouin","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.18240\/ijo.2019.11.17","article-title":"The correlation between keratoconus and eye rubbing: A review","volume":"12","author":"Najmi","year":"2019","journal-title":"Int. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0161-6420(02)01287-3","article-title":"Atopy: A patient-specific risk factor for diffuse lamellar keratitis","volume":"110","author":"Boorstein","year":"2003","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2017.09.052","article-title":"Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials","volume":"78","author":"Fleming","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/0974-9233.124082","article-title":"Refractive surgery in systemic and autoimmune disease","volume":"21","author":"Alkharashi","year":"2014","journal-title":"Middle East Afr. J. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaad.2021.06.017","article-title":"Management of inadequate response and adverse effects to dupilumab in atopic dermatitis","volume":"86","author":"Narla","year":"2022","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/12\/3273\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:25:54Z","timestamp":1760138754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/12\/3273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jcm11123273"],"URL":"https:\/\/doi.org\/10.3390\/jcm11123273","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]}}}